ArticleJournal of substance abuse treatment2016
Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use.
Article in Journal of substance abuse treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 5 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Physician Reluctance to Intervene in Addiction: A Systematic Review.JAMA network open · 2024Pooled it
- Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence.Drug and alcohol dependence · 2021Pooled it
- A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.Journal of substance abuse treatment · 2020Pooled it
- Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.Addiction science & clinical practice · 2019Pooled it
- Extended-release injectable naltrexone for opioid use disorder: a systematic review.Addiction (Abingdon, England) · 2018Pooled it
- Enhancing Use of Medications for Opioid Use Disorder Through External Coaching.Psychiatric services (Washington, D.C.) · 2023Trial
- Wait No Longer: Reducing Medication Wait-Times for Individuals with Co-Occurring Disorders.Journal of dual diagnosisTrial
- Optimizing outpatient pharmacologic treatment for veterans with alcohol use disorder using an academic detailing approach for primary care providers in the United States Department of Veterans Affairs: A retrospective quasi-experimental study.Addiction (Abingdon, England) · 2026Article
- Implementation opportunities for optimizing retention on buprenorphine treatment for people with opioid use disorder in West Virginia.Drug and alcohol dependence · 2025Article
- Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs.JAMA network open · 2025Article
- Buprenorphine prescribing practices for older adults in 2019 and 2020.Journal of the American Geriatrics Society · 2025Observational
- Lessons from the National institutes of health innovation corps program: defining barriers to developing and commercializing novel solutions for persons with opioid use disorder.Addiction science & clinical practice · 2025Article
- Development and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose.Nature communications · 2025Article
- Social Network Barriers to Extended-Release Naltrexone Within Rural Appalachia: Perspectives from Justice-Involved Clients and Clinicians.Substance use & misuse · 2025Article
- Dissemination of health content through social networks: YouTube and opioid use disorders.Journal of substance use and addiction treatment · 2024Review
- Considerations when prescribing opioid agonist therapies for people living with HIV.Expert review of clinical pharmacology · 2024Review
- A Qualitative Exploration of the Potential Role of Using Online Social Media Support Communities to Increase Initiation of Medications for Opioid Use Disorder (MOUD).Journal of substance use · 2023Article
- Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study.Journal of substance abuse treatment · 2022Article
- Provider perspectives on emergency department initiation of medication assisted treatment for alcohol use disorder.BMC health services research · 2022Article
- Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
The Medication Research Partnership (a national health plan and nine addiction treatment centers contracted with the health plan) sought to facilitate the adoption of pharmacotherapy for alcohol and opioid use disorders. Qualitative analysis of interviews with treatment center change leaders, individuals working for the manufacturer and its technical assistance contractor, and health plan managers extracted details on the processes used to order, store, bill for, and administer extended-release naltrexone. Qualitative themes were categorized using domains from the Consolidated Framework for Implementation Research (intervention characteristics, outer setting, inner setting, and provider characteristics). Characteristics of XR-NTX that inhibited use included the complexity of ordering and using the medication; cost was also a barrier. Outer setting barriers reflected patient needs and external health plan policies on formulary coverage, benefit management, and reimbursement. Program structures, the lack of physician linkages, a culture resistant to the use of medication, and unease with change were inner setting elements that limited use of XR-NTX. Patient stereotypes and a lack of knowledge about XR-NTX affected practitioner willingness to treat patients and prescribe XR-NTX. The Consolidated Framework for Implementation Research provided a useful lens to understand and interpret the processes affecting access to XR-NTX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.